Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
5.56
+0.78 (16.32%)
At close: Jun 6, 2025, 4:00 PM
5.58
+0.02 (0.36%)
After-hours: Jun 6, 2025, 7:17 PM EDT
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
179.01M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SGMT News
- 2 days ago - Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567 - Seeking Alpha
- 2 days ago - Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis - GlobeNewsWire
- 15 days ago - Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025 - GlobeNewsWire
- 4 weeks ago - Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - GlobeNewsWire
- 3 months ago - Sagimet Biosciences' Denifanstat Should Be Worth More Today - Seeking Alpha
- 7 months ago - Sagimet: More Than Just A MASH Drug Development Biotech - Seeking Alpha